Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE

Bibliographic Details
Main Authors:	Melinda J. Gooderham, MSc, MD, FRCPC, Chia-Yu Chu, MD, PhD, Ricardo Rojo, MD, Hernan Valdez, MD, Pinaki Biswas, PhD, Michael C. Cameron, MD, Claire Feeney, MD, PhD, Gerardo A. Encinas, MD, MHS, Kathleen Peeples-Lamirande, PharmD, MPH, Joseph C. Cappelleri, PhD, Daniela E. Myers, MPH, Marco DiBonaventura, PhD
Format:	Article
Language:	English
Published:	Elsevier 2021-09-01
Series:	JAAD International
Subjects:	atopic dermatitis combination therapy cost abrocitinib economic impact monotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666328721000341

id	doaj-13593df58a0348208ccd60f8f06ab9a3
record_format	Article
spelling	doaj-13593df58a0348208ccd60f8f06ab9a32021-08-12T04:35:48ZengElsevierJAAD International2666-32872021-09-0144648Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPAREMelinda J. Gooderham, MSc, MD, FRCPC0Chia-Yu Chu, MD, PhD1Ricardo Rojo, MD2Hernan Valdez, MD3Pinaki Biswas, PhD4Michael C. Cameron, MD5Claire Feeney, MD, PhD6Gerardo A. Encinas, MD, MHS7Kathleen Peeples-Lamirande, PharmD, MPH8Joseph C. Cappelleri, PhD9Daniela E. Myers, MPH10Marco DiBonaventura, PhD11SKiN Centre for Dermatology, Peterborough, Ontario, CanadaDepartment of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanPfizer Inc, Groton, ConnecticutPfizer Inc, New York, New YorkPfizer Inc, New York, New YorkPfizer Inc, New York, New YorkPfizer Ltd, Surrey, United KingdomPfizer Inc, Vancouver, CanadaPfizer Inc, Collegeville, PennsylvaniaPfizer Inc, Groton, ConnecticutPfizer Inc, Collegeville, PennsylvaniaPfizer Inc, New York, New York; Correspondence to: Marco DiBonaventura, PhD, 235 East 42nd Street, New York, NY 10017http://www.sciencedirect.com/science/article/pii/S2666328721000341atopic dermatitiscombination therapycostabrocitinibeconomic impactmonotherapy
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Melinda J. Gooderham, MSc, MD, FRCPC Chia-Yu Chu, MD, PhD Ricardo Rojo, MD Hernan Valdez, MD Pinaki Biswas, PhD Michael C. Cameron, MD Claire Feeney, MD, PhD Gerardo A. Encinas, MD, MHS Kathleen Peeples-Lamirande, PharmD, MPH Joseph C. Cappelleri, PhD Daniela E. Myers, MPH Marco DiBonaventura, PhD
spellingShingle	Melinda J. Gooderham, MSc, MD, FRCPC Chia-Yu Chu, MD, PhD Ricardo Rojo, MD Hernan Valdez, MD Pinaki Biswas, PhD Michael C. Cameron, MD Claire Feeney, MD, PhD Gerardo A. Encinas, MD, MHS Kathleen Peeples-Lamirande, PharmD, MPH Joseph C. Cappelleri, PhD Daniela E. Myers, MPH Marco DiBonaventura, PhD Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE JAAD International atopic dermatitis combination therapy cost abrocitinib economic impact monotherapy
author_facet	Melinda J. Gooderham, MSc, MD, FRCPC Chia-Yu Chu, MD, PhD Ricardo Rojo, MD Hernan Valdez, MD Pinaki Biswas, PhD Michael C. Cameron, MD Claire Feeney, MD, PhD Gerardo A. Encinas, MD, MHS Kathleen Peeples-Lamirande, PharmD, MPH Joseph C. Cappelleri, PhD Daniela E. Myers, MPH Marco DiBonaventura, PhD
author_sort	Melinda J. Gooderham, MSc, MD, FRCPC
title	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
title_short	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
title_full	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
title_fullStr	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
title_full_unstemmed	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
title_sort	economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: results from jade mono-2 and jade compare
publisher	Elsevier
series	JAAD International
issn	2666-3287
publishDate	2021-09-01
topic	atopic dermatitis combination therapy cost abrocitinib economic impact monotherapy
url	http://www.sciencedirect.com/science/article/pii/S2666328721000341
work_keys_str_mv	AT melindajgooderhammscmdfrcpc economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT chiayuchumdphd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT ricardorojomd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT hernanvaldezmd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT pinakibiswasphd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT michaelccameronmd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT clairefeeneymdphd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT gerardoaencinasmdmhs economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT kathleenpeepleslamirandepharmdmph economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT josephccappelleriphd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT danielaemyersmph economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare AT marcodibonaventuraphd economicimpactofabrocitinibmonotherapyandcombinationtherapyinpatientswithmoderatetosevereatopicdermatitisresultsfromjademono2andjadecompare
_version_	1721209735802257408

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE

Similar Items